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Forewords 
 
‘Medications in recovery’ – 2012’s report from the Recovery 
Orientated Drug Treatment (RODT) expert group – provided 
drug treatment commissioners and services with invaluable 
advice on how to ensure drug dependent patients’ recovery 
ambitions can be best realised while ensuring their continued 
protection from the risks of relapse to drug use. Earlier this 
year, I asked John Strang to reconvene the expert group to 
provide me with some further advice on the frequency and 
content of treatment reviews that can ensure continued 
treatment benefit. I am grateful to Professor Strang and his 
group for quickly and effectively providing me with that 
advice, which Public Health England’s Alcohol and Drug 
team has then framed for the benefit of commissioners and 
services. 
 
Professor Dame Sally Davies, Chief Medical Officer
 
 
 
It is vital to review the progress of any medical treatment and 
to tailor treatment accordingly. This supplementary report 
from the RODT expert group describes the nature of the 
different review processes that should take place during drug 
treatment to ensure that patients are deriving the most 
benefit possible from the available interventions. Review is 
both an integral and ongoing part of every contact with a 
patient, and a periodic opportunity to step back and more 
thoroughly review the interventions being provided and the 
individual patient’s response to them. If greater benefit might 
be derived from changing the interventions, their intensity or 
their setting, then review provides the information and 
opportunity for patient and clinician to revise the treatment 
plan. 
 
Professor John Strang, Chair, Recovery Orientated 
Drug Treatment Expert Group 
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Introduction and summary 
In 2012, the Recovery Orientated Drug Treatment Expert Group published its 
report, Medications in recovery: re-orientating drug dependence treatment. 
The report supports a radical ambition to place prescribing within a fully 
recovery-orientated system of care, with changes at system, service and 
individual levels. The report makes clear that this involves treatment services 
continuing to re-orient their delivery of care to provide active and visible 
support for recovery from the point of entry to treatment, during treatment and 
after exit, and that successful recovery also relies on support from others, 
including mutual aid, employment and housing services. 
In the summer of 2013, the Chief Medical Officer (CMO) asked for further 
advice from the expert group on: 
 the frequency at which an individual receiving treatment for addiction 
should be reviewed (to determine the benefit of the treatment and thus 
whether alternative treatments should be tried) 
 the structure of the review meetings (what should be considered, how to 
assess the benefit a patient is receiving, tools for decision making, etc) 
 
The group responded to CMO in September 2013 and, following her review of 
their advice, she has agreed with the group that PHE should publish the 
advice for the benefit of the field. 
The group’s advice makes clear that: 
 care planning, with its ongoing and planned reviews of specific goals and 
actions, should be part of a phased and layered treatment programme 
 a strategic review of the client’s recovery pathway will normally be 
necessary within three months (and no later than six months) of treatment 
entry, and will then usually be repeated at six-monthly intervals 
 a strategic review should always revisit recovery goals and pathways (to 
support clients to move towards a drug-free lifestyle) 
 drug treatment should be reviewed based on an assessment of 
improvement (or preservation of benefit) across the core domains of 
successful recovery. 
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To enable this clinical advice to be followed locally, commissioners will want 
to ensure their services: 
 have the resources (sufficient staff, with appropriate competences and the 
time) to conduct ongoing, specific and strategic reviews as specified 
 monitor a range of recovery outcomes to understand and demonstrate the 
benefits being derived from treatment 
 have access to a diverse range of interventions, intensities and settings 
(including residential) to optimise treatment and care  
 
PHE’s forthcoming ‘Turning evidence into practice’ briefing on optimising 
opioid substitution treatment will also be useful to commissioners and 
providers. 
The group sets its advice within the context that: 
 effective review of progress in treatment plays a key role in the continuing 
ambition for treatment to be sensitive to the needs and circumstances of 
each patient, and purposeful and adaptive in its approach 
 dependent drug use is a severe and multi-dimensional disorder causing 
impairment across health domains and, crucially, extending into non-
health domains 
 effective drug treatment provides benefits and improvements across these 
domains 
 for some people, early abstinence is achievable and must be supported 
but, for many, despite effective treatment provided, dependent drug use is 
a long-term disorder – often with periods of remission – with intermittent 
acute episodes. Both short- and long-term considerations are important to 
improve long-term benefit 
 the risk of premature death is increased by drug use and, in the long-term, 
reduced in treatment. There is also a transient elevated risk of death in the 
very early stages of treatment and, briefly, following the end of treatment 
 these risks require careful assessment and attention to medication dose 
and compliance, and to other relapse risks. Strategic reviews balance 
support for recovery steps – and fully-informed risk-taking to achieve them 
– and reduction of risk of premature drop-out and avoidable harm and 
death 
 effective assessment involves service users in the planning of their care, 
and covers all key dimensions of their life, to lead to clarity on goals, and 
plans to develop support and skills to reduce risks 
 drug treatment often occurs in episodes and its benefits are iterative, 
building over time to reduce the risk of future relapse 
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 a wide range of intervention options – at different intensities and changing 
during the course of treatment – needs to be available 
 reviews aim to maintain or modify treatment and recovery interventions – 
and other supports – to sustain or improve the patient’s response and 
recovery 
 support should continue after the end of formal treatment to monitor, 
maintain and support recovery, provide additional support over critical 
transitional periods, and provide rapid access back into treatment at the 
first sign of relapse 
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Responding to particular findings in a review 
Finding Possible response 
Demonstrated 
adherence to and 
stability on opioid 
substitution treatment 
Introduce option of some take-home doses 
Further good 
continued medication 
adherence and 
clinical benefit 
Extend provision of take-home doses 
Deterioration of 
adherence to opioid 
substitution treatment  
Reinstate supervised dosing, along with a 
schedule of earlier re-review 
Benefit previously 
achieved from OST 
but no further accrual 
of benefit occurring 
Examine whether benefit is still being 
achieved and has reached a plateau (and 
decide whether it should be usefully 
continued), or whether the treatment is now 
no longer necessary. Any change in medical 
management, such as reduction or cessation 
of protective medication, should be applied 
cautiously, with contingent arrangements in 
place for revision of the care plan in the event 
of the recurrence of the condition being 
treated. 
Benefit from 
treatment appears 
less than originally 
anticipated 
Consider the progress of the patient over the 
longer period and recognise partial degrees of 
benefit, as these can be important for the 
patient and for society (e.g. cessation of 
injecting, cessation of crime, improved 
physical or psychological health, improved 
parenting). Consider adjustments or 
supplementary interventions that may 
increase the effectiveness of the interventions. 
No appearance of 
benefit being 
achieved 
Re-consider the wider range of available 
interventions and, if agreed suitable, make 
arrangements to access alternative 
treatments. 
Good progress Step up the recovery support being provided, 
such as accelerating access to education and 
employment opportunities, and providing 
options to support others in their recovery. 
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Re-orientating drug dependence 
treatment: supplementary advice on 
the frequency and context of reviews 
1 The frequency and timing of care plan review, including 
strategic review 
“The frequency at which an individual receiving treatment for 
addiction should be reviewed (to determine the benefit of the 
treatment and thus whether alternative treatments should be 
tried)” 
1.1 Ongoing clinical review must be part of every one-to-one, structured 
appointment between the patient and their keyworker. 
1.2 In addition to this ongoing process of monitoring of care (which can 
lead to updating of specific elements of the care plan), there are 
planned reviews of particular actions and goals, and comprehensive 
'strategic' reviews of progress. 
1.3 For patients who are on treatment that includes opioid substitution 
treatment, strategic reviews will normally be necessary within three 
months (and no later than six months) of treatment entry. It will then 
usually be repeated at six-monthly intervals, although this interval may 
be shortened (or in carefully considered cases extended) in the light of 
the findings from the previous review and in agreement with the patient. 
1.4 The group gave careful consideration to whether there should be a 
fixed scheduling of the exact timings of reviews. It concluded that, 
rather than a fixed timetable, decisions on frequency should be 
personalised and deliberative, taking into account the patient’s 
circumstances and progress. 
1.5 The frequency of strategic review can often be reduced when the 
patient is deriving clear benefit from the interventions currently being 
provided and no significant change to treatment over the coming period 
is envisaged. In this circumstance, ongoing reviews would examine 
whether adjustment to the care plan has the potential to increase 
benefit further. 
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1.6 Review is likely to be called earlier and more frequently for patients 
who are early in their treatment; who are on treatments of short-term 
duration; whose condition is complex, comorbid or problematic; for 
whom treatment is not producing the expected benefits; and at times of 
personal transition or changes in setting and situation. 
1.7 Reviews should continue after treatment (i.e. after the end of a specific 
element of treatment, such as conclusion of detox, conclusion of OST, 
or conclusion of period of in-patient care or residential rehab) in the 
form of pre-scheduled recovery check-ups that monitor recovery, allow 
for recovery supports to be maintained or increased, and provide rapid 
access back into treatment at early signs of relapse risk. 
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2 Elements of strategic review processes 
“The structure of the review meetings (what should be 
considered, how to assess the benefit a patient is receiving, tools 
for decision making, etc).” 
2.1 There is no single format for strategic review but the patient should 
always be the central participant 
2.2 Where there are high risks, involving multiple contributors, a full 
multidisciplinary and multi-agency meeting with the patient, to review 
the overall recovery care plan, may be appropriate, and in inpatient and 
residential settings, such reviews may be the norm. 
2.3 However organised, the strategic review should be rigorous. It must 
always involve a 'stepping-back' overview of the care plan previously 
agreed with the patient. 
2.4 In some cases, the keyworker may best review the care and progress 
of their patient as part of that keyworker's reflective practice and 
professional development, within supervision and within 
multidisciplinary team support and overview arrangements. Where any 
such strategic supervision may take place in the absence of a patient, 
the review should only be considered complete when this has properly 
involved the patient (usually before and after), and when any decision 
that has been made to amend or to maintain the current recovery care 
plan, between the patient and the keyworker, has followed in light of 
that involvement. 
2.5 Leading a review requires expertise and knowledge. A senior 
practitioner will usually lead a strategic review, especially when 
treatment includes prescribing. This senior practitioner must be skilled 
in the addictions field and knowledgeable about the diversity of 
treatment options and the associated quality evidence bases (eg, 
NICE, Cochrane, DH Guidelines), as well as the potential confounding 
factors such as co-morbidities. The practitioner needs to be provided 
with effective administrative and keyworker support to ensure they 
have ready access to all relevant information and to make most 
efficient use of their time. 
2.6 Other relevant people to involve in the strategic review process, in 
addition to the keyworker, patient and senior practitioner, might include 
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team psychologists, nurses, doctors and recovery workers; relevant 
third-parties (eg, perspectives from the patient's family, partner or 
employer); extended team members (such as dispensing pharmacists 
and social workers); and workers from other agencies involved (such 
as skill-support/reintegration workers and probation officers). In 
practical terms, how these relevant inputs are obtained will vary from 
case to case. 
2.7 A broad range of indicators and measures of treatment benefit and 
recovery need to be considered in strategic review. Fundamentally, 
these will include both the progress on the current recovery care plan 
goals and actions, and also the progress, or otherwise, that has been 
made since initial entry to treatment. This consideration of progress 
should also include any other measures relevant to a patient's gains (or 
losses) in recovery capital and in addressing identified 
problems/pathology, including objective measures that are available. 
2.8 The patient’s self-report and comments from the family (and any 
significant others) are also important elements of the review. 
2.9 Objective measures and indicators will typically include:  
 scores from the Treatment Outcomes Profile (TOP), including 
measures of physical health and psychological wellbeing 
 drug testing results (ie, compilation of results from urine-testing, 
and/or breathalyser and or other newer possible methods such as 
saliva or sweat testing for drugs), as a measure of (i) compliance 
with prescribed medication, (ii) stopping problem drug use, and (iii) 
to corroborate the patient’s self-report 
 independent assessment and/or measures of stability/recovery: 
employment, housing, engagement with family, taking responsibility 
for childcare, etc 
 compliance with pharmacy attendance and with supervised dosing 
requirements (eg, reports back from dispensing and supervising 
community pharmacists) 
 
2.10 In order to avoid undue focus only on current care plan goals and 
interventions, the strategic review needs to measure improvements 
with regard to the primary diagnosis and the main problem drug (or 
drug class) and then consider the possible co-existence of other 
addictive problems and other co-morbidities. The review needs to re-
assess the current state of progress in all the core assessment and 
care planning domains: drug and alcohol use (including associated 
Medications in recovery: best practice in reviewing treatment 
13 
hazardous behaviours such as injecting and sharing equipment), 
physical and psychological health, criminal involvement and offending, 
and social functioning. The relative balance of importance of each and 
the nature of what is considered will change according to the individual 
and their progress. 
2.11 It is important that strategic reviews do not become unduly narrow in 
focus, particularly for those patients who have received prescribed 
substitute or other medication. The review should specifically consider 
both the medications being prescribed and other interventions being 
provided, and the benefit being derived from each (and possible 
interplay or potential positive or negative interactions). Successful 
progress in recovery for those on substitute medication, whilst needing 
properly to take account of the continued use of any necessary 
medication, must be based on assessment of improvements (or 
otherwise) across all the core domains of successful recovery. 
2.12 It is important that all reviews, including strategic reviews, are focused 
on adding real value to care, as efficiently and effectively as possible. 
Reviews should not be rigid and formulaic but should reflect the place 
of the individual in their recovery journey. In general, one may expect 
the emphasis of such reviews to be different for different stages of the 
recovery journeys. Early on, reductions of hazardous patterns of drug 
use, arrangements for substitute prescribing, treatment of comorbid 
problems and/or support for emergency housing may be key strategic 
focuses for those commencing opioid substitution treatments, 
alongside early consideration of the potential trajectories for successful 
exits; while at a later stage, skill assessments and development, 
therapeutic family work and improving social relations may have a 
greater focus for the strategic reviews, and involve more and different 
contributors. As treatment and recovery progress, it is appropriate for 
the goals and actions of recovery care plans to be increasingly self-
managed by the patient. 
2.13 The group’s 2012 report addressed the need for purposeful, adaptive 
treatment and recommended a phased and layered approach, which 
includes a full range of community and residential treatment options, 
available to respond to an individual’s changing needs or the failure of 
a particular course of action to deliver clear benefit. 
2.14 If difficulties are encountered in optimising treatment and care due to 
problems in accessing the diverse menu of interventions, intensities 
and settings (including residential) so as to impair recovery, it is 
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important that this is recorded as part of strategic reviews and for it to 
be reported within teams, with provider organisations and to 
commissioners as evidence of possible unmet need locally. 
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Appendix A – Evidence-based guidance 
There is already extensive evidence-based guidance relevant to any review of 
processes to guide clinicians, and which the group have reflected in preparing 
this note. The guidance includes: 
 Technology Appraisals and Clinical Guidelines from the National Institute 
for Health and Care Excellence 
o NICE (2007) Drug misuse: opiate detoxification. NICE Clinical 
Guideline 52. London: National Institute for Health and Clinical 
Excellence 
o NICE (2007) Drug misuse: psychosocial interventions. NICE Clinical 
Guideline 51. London: National Institute for Health and Clinical 
Excellence 
o NICE (2007) Methadone and buprenorphine for the management of 
opioid dependence. NICE Technology Appraisal guidance 114. 
London: National Institute for Health and Clinical Excellence 
o NICE (2007) Naltrexone for the management of opioid dependence. 
NICE Technology Appraisal guidance 115. London: National Institute 
for Health and Clinical Excellence 
NB The above technology appraisals and clinical guidelines were 
reviewed by NICE in 2010 and 2011 respectively, when they decided no 
new evidence had been published that was likely to have a material effect 
on the guidance, which therefore remains current in 2013. 
 The 2007 Clinical Guidelines 
o Department of Health (England) and the devolved administrations 
(2007) ‘Drug Misuse and Dependence: UK Guidelines on Clinical 
Management’. London: Department of Health (England), the Scottish 
Government, Welsh Assembly Government and Northern Ireland 
Executive 
 Cochrane reviews 
o Cochrane Database of Systematic Reviews – over 50 drug 
dependence reviews available at www.thecochranelibrary.com 
 The National Treatment Agency’s care planning practice guide 
o NTA (2006) Care Planning Practice Guide. London: National 
Treatment Agency for Substance Misuse. 
 The RODT group’s 2012 report 
o Recovery Orientated Drug Treatment Expert Group (2012) Medications 
in Recovery: Re-Orientating Drug Dependence Treatment. London: 
National Treatment Agency for Substance Misuse. 
 
Medications in recovery: best practice in reviewing treatment 
16 
Appendix B – The context for reviewing progress 
As our 2012 report1 made clear, there is “an accessible, evidence-based, 
drug treatment system in every part of England”. It is highly effective but 
needs constant vigilance to ensure that it is firmly rooted in the evidence base 
while also being sensitive to the different needs and circumstances of each 
individual patient, being ambitious for the individual, and being purposeful and 
adaptive in its approach. Effective review of progress in treatment plays a key 
role in that ambition. 
Dependent drug use is a severe and multi-dimensional disorder causing 
impairment across health domains and, crucially, extending into non-health 
domains such as crime, child protection, and inter-generational transfer. It can 
have a profound impact on an individual’s life and functioning, and 
relationships, and lead to social deterioration. 
Effective drug treatment provides benefits and improvements across these 
domains. 
While, for some people, early abstinence is achievable and must be 
supported, for many, despite effective treatment provided, the pattern of 
dependent drug use is that of an acute-on-chronic disorder, in which a long-
term disorder, often with periods of remission, has intermittent acute 
episodes. In the addiction treatment field, both the short-term and the long-
term considerations are important, in order to improve long-term benefit. 
The risk of premature death is increased by drug use and, in the long-term, 
reduced in treatment. But there is also a transient elevated risk of death in the 
very early stages of treatment and, briefly, following the end of treatment, 
which requires careful assessment of risk, and attention to dosing of any 
medications, medication compliance and to other risk factors for relapse that 
may usefully still be addressed prior to departure from treatment. In view of 
the known risks of fatality in the initial weeks of abstinence or after leaving 
treatment, care plans need to incorporate knowledge and understanding of 
the risks and the development of patients' skills needed to reduce or minimise 
them. Balancing support for optimistic, abstinence-based recovery steps – 
and fully-informed risk-taking to achieve this – and supporting reduction of 
risk of premature drop-out and avoidable harm and death, is an important 
                                            
 
1
 Recovery Orientated Drug Treatment Expert Group (2012) Medications in Recovery: Re-
Orientating Drug Dependence Treatment. London: National Treatment Agency for Substance 
Misuse. 
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contextual issue within which strategic reviews of care always take place, and 
need to be addressed with the patient. 
Effective assessment at the beginning of treatment focuses on active 
involvement of the patient in all elements of the assessment and planning of 
care, and covers all key dimensions of their life, to lead to clarity on the 
agreement of positive and realistic goals, and those plans to develop support 
and skills to reduce key risks. 
Drug treatment is holistic, addressing all the domains of a patient’s life and 
functioning. Because of the nature of the condition, it often occurs in episodes 
and is iterative, building over time to enable the patient to derive health 
benefit and to reduce the risk of future relapse. 
To do this, a wide range of intervention options – at different intensities and 
changing during the course of treatment – needs to be available, including 
social supports that involve the family or peers. Where there are only limited 
opportunities to address an individual's identified key needs, such as for 
education, training or stable housing, this can limit the effectiveness of any 
review process. 
Reviewing treatment interventions, the benefits derived from them and the 
progress the patient is making, is an ongoing and integral part of treatment, of 
the therapeutic alliance between patient and practitioner, and of an effective 
practitioner’s reflective practice. In addition to regular and frequent keyworker 
review, there will also be specific dated reviews of goals and actions within 
the patient’s care plan, and more intensive and strategic review processes in 
which those involved in the patient’s care ‘step back’ and analyse the 
patient’s care and response with the benefit of collected data and other 
information, and input from colleagues. 
Whatever the form of reviews, the aim will be to maintain or modify the 
treatment and recovery interventions, and other supports being provided, in 
order to sustain or improve the patient’s response and recovery. 
Support for the patient does not end with treatment. It needs to monitor, 
maintain and support continuing and accumulating recovery, provide any 
necessary additional structure and support over critical transitional periods, 
and provide rapid access back into treatment at the first sign of relapse. 
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Appendix C – Scenarios for possible responses to a review’s findings 
The 2007 Clinical Guidelines2 already describe some possible responses to 
patients failing to benefit from treatment for specified reasons. They also 
cover consideration of possible termination of a failing treatment. Based on 
these considerations, what follows is a more detailed description of how 
reviewers might need to respond to particular findings in a review. 
1. For patients being prescribed opioid substitution treatments (usually oral 
methadone or sublingual buprenorphine), the findings at review will guide 
consideration of modification of arrangements for dispensing, such as 
potential introduction of provision of take-home doses for a patient with 
demonstrated stability, and extension of this provision after later evidence 
of good continued medication adherence following earlier introduction of 
take-home doses. However if evidence is elicited of deterioration of 
adherence, then reinstatement of supervised dosing would often follow, 
along with a schedule of earlier re-review.  
2. For patients where benefit has been achieved through opioid substitution 
treatment but where no further accrual of benefit is occurring, the senior 
clinician and the patient need to use the occasion of the review to examine 
whether benefit is still being achieved and has reached a plateau (and a 
decision made about whether it should be usefully continued), or whether 
the treatment is now no longer necessary. It is often difficult to make a 
correct judgement, in much the same way as when good benefit has been 
achieved with medications in the treatment of other conditions such as 
depression, epilepsy and hypertension. In each instance, any change in 
medical management, such as reduction or cessation of the protective 
medication, should be applied cautiously, with prior plans for revision of 
the care plan in the event of the earliest signs of recurrence of the 
condition being treated. Furthermore this increased vigilance and support 
are particularly important over any such planned period of medication 
change, and in the period following.  
3. For patients where benefit from treatment appears less than originally 
anticipated, the senior reviewer must make sure to consider the progress 
of the patient over the longer period and be able to recognise partial 
degrees of benefit, as these can be important for the patient and for 
society (e.g. cessation of injecting, cessation of crime, improved physical 
                                            
 
2
 Department of Health (England) and the devolved administrations (2007) Drug Misuse and 
Dependence: UK Guidelines on Clinical Management. London: Department of Health 
(England), the Scottish Government, Welsh Assembly Government and Northern Ireland 
Executive 
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or psychological health, improved parenting). The purpose of the review 
should then include consideration of adjustments or supplementary 
interventions that may increase the effectiveness of the interventions.    
4. For patients where it appears that no benefit is being achieved, the senior 
reviewer and the patient need to re-consider the range of available 
interventions and, if agreed suitable, make arrangements to access 
alternative treatments. 
5. For a patient making good progress, it will likely be appropriate to step up 
the recovery support being provided, such as accelerating access to 
education and employment opportunities, and providing options to support 
others in their recovery. 
6. The aim of the clinician will be to gradually step back as the patient 
becomes more in control of managing their condition and their recovery. 
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